http://www.fiercebiotech.com/story/...phiii-diabetes-blockbuster-hopeful/2012-05-22
"The FDA's demanding requirements on cardio safety data has made diabetes one of the most challenging diseases in the drug development world. Today, Eli Lilly ($LLY) demonstrated that its late-stage diabetes drug dulaglutide cleared an important cardiovascular safety hurdle, impressing analysts with a savvy clinical game plan on an important experimental product in its pipeline."
"The FDA's demanding requirements on cardio safety data has made diabetes one of the most challenging diseases in the drug development world. Today, Eli Lilly ($LLY) demonstrated that its late-stage diabetes drug dulaglutide cleared an important cardiovascular safety hurdle, impressing analysts with a savvy clinical game plan on an important experimental product in its pipeline."